

OUR PIPELINE IS STARTING TO DELIVER VALUE

WAVE 1¹

CLINICAL-STAGE NMEs

WAVE 2²

POTENTIAL APPROVAL	FY21	FY22	FY23	FY24	FY25 and Beyond				
ONCOLOGY	mococertinib 2L NSCLC with EGFR exon 20 insertion mutation	pevonedistat HR-MDS	mococertinib 1L NSCLC with EGFR exon 20 insertion mutation	pevonedistat Unfit AML TAK-007 CD19+ hematologic malignancies	TAK-981 Multiple cancers	TAK-676 Solid tumors	TAK-252 Solid tumors	TAK-102 Multiple cancers	
RARE GENETICS & HEMATOLOGY	maribavir R/R CMV infect. in transplant	TAK-609 Hunter CNS (IT) ⁴	maribavir 1L CMV infect. in HSCT TAK-755 cTTP	TAK-611 MLD (IT)	TAK-755 ITTP, SCD	mezagitamab MG, ITP	TAK-607 Complications of prematurity		
NEUROSCIENCE			soticlestat DS soticlestat LGS	Orexin 2R-ag TAK-994 Narcolepsy T1	Orexin 2R-ag (TAK-994/TAK-861/TAK-925) NT2, IH, Additional Indications		TAK-653⁵ Inadequate resp. in MDD		
GASTRO-ENTEROLOGY	Eohilia³ EoE Approval date TBD				TAK-071 Parkinson's Disease	TAK-341 Parkinson's Disease	TAK-041⁵ Anhedonia in MDD		
					TAK-999 AATD Liver Disease	TAK-062 Celiac Disease	TAK-101 Celiac Disease	sibofimloc Crohn's Disease (post-op and ileitis)	TAK-510 Nausea & vomiting
VACCINES	TAK-019 Novavax COVID-19 Vaccine (JP)	TAK-003 Dengue Vaccine ⁶			TAK-906 Gastroparesis	TAK-954 POGD	TAK-951 Nausea & vomiting	TAK-039 Hepatic encephalopathy	
	COVID-19 Vaccine Moderna Intramuscular Injection (JP)				TAK-426 Zika Vaccine				

● U.S. Breakthrough and/or Fast Track Designations

● China Breakthrough and/or Japan SAKIGAKE Designation

~~ORPH~~ Orphan potential in at least one indication

 Orexin franchise

 APPROVED

- Potential approval dates depend on data read-outs; some WAVE 1 target approval dates assume accelerated approval
- Certain WAVE 2 programs may be accelerated into WAVE 1 depending on future data read outs
- In active discussions with the FDA. Potential approval subject to outcome of discussions
- Filing of TAK-609 is subject to feedback from FDA on the ongoing extension trial and may change

- Partnership with Neurocrine Biosciences
- Timeline change: TAK-003 (FY22), expect CHMP Opinion in FY21
Removed from NME pipeline: TAK-831, TAK-671, TAK-214. Details of partnership updates in slide 8 and Quarterly Financial Report.
Takeda's Fiscal Year ends March 31 of the following year; e.g., "FY21" refers to the twelve-month period ending March 31, 2022. All timelines are approximate estimates of July 30, 2021. For glossary of disease abbreviations please refer to appendix.

MAXIMIZING THE VALUE OF OUR GLOBAL AND REGIONAL BRANDS

	PHASE 1 & 2	PHASE 3			FILED			
ONCOLOGY		<p>NINLARO[®] Proteasome inhibitor Maint. ND MM post-SCT (US, EU)</p> <p>NINLARO[®] Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN)</p>	<p>ICLUSIG[®] BCR-ABL inhibitor FL Ph+ ALL (US)</p> <p>ALUNBRIG[®] ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)</p>	<p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor mCRPC combo w/atezolizumab (JP)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 2L mNSCLC combo w/atezolizumab (JP)</p>	<p>ALUNBRIG[®] ALK inhibitor 1L & 2L ALK+NSCLC (CN)</p> <p>NINLARO[®] Proteasome inhibitor Maint. ND MM no SCT (JP)</p>	<p>ADCETRIS[®] <i>Seattle Genetics</i> CD30 ADC CTCL (CN)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)</p>		
RARE GENETICS & HEMATOLOGY	<p>NATPARA[®] PTH replacement Hypothyroidism (JP)</p>	<p>TAKHZYRO[®] Anti-kallikrein mAb HAE pediatric (GL)</p>	<p>TAKHZYRO[®] Anti-kallikrein mAb BMA (GL)</p>	<p>ADYNOVATE[®] recombinant Factor VIII Pediatric HemA (EU)</p>	<p>VONVENDI[®] vWF replacement vWD Pediatric on-demand & surgery (GL)</p>	<p>TAKHZYRO[®] Anti-kallikrein mAb HAE (JP)</p>	<p>VONVENDI[®] vWF replacement vWD Adult Prophylaxis (GL)</p>	
NEUROSCIENCE								
GASTRO-ENTEROLOGY	<p>ENTYVIO[®] α4β7 mAb Pediatric UC/CD (GL)</p>	<p>ENTYVIO[®] α4β7 mAb SubQ CD (US, JP)</p> <p>ENTYVIO[®] α4β7 mAb GvHD Prophylaxis (EU, JP)</p>	<p>Vonoprazan PCAB H. Pylori (CN)</p> <p>ALOFISEL[®] mesenchymal stem cells Perianal Fistulas in CD (US)</p>	<p>ENTYVIO[®] α4β7 mAb SubQ UC (US, JP)</p> <p>ENTYVIO[®] α4β7 mAb Antibiotic-refractory Pouchitis (EU)</p>	<p>Vonoprazan PCAB Reflex Esophagitis Maintenance (CN)</p> <p>Vonoprazan PCAB Oral disintegrated tablet formulation (JP)</p>	<p>GATTEX[®] GLP-2R agonist Pediatric-SBS (JP)</p> <p>GATTEX[®] GLP-2R agonist Adult-SBS (JP)</p> <p>ALOFISEL[®] mesenchymal stem cells Perianal Fistulas in CD (JP)</p>		
VACCINES								
PDT		<p>CUVITRU[®] IgG 20% (human) subcutaneous PID (JP)</p>	<p>HYQVIA[®] <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU)</p>	<p>HYQVIA[®] <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)</p>	<p>HYQVIA[®] <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase HyHub Device (US)</p>			

● Orphan Drug Designation (in any region / indication for a given asset) ✓ Approved since Q4 FY20

Status as of July 30, 2021; GL = global (USA, Europe, Japan, China). Pipeline not all inclusive; programs also ongoing in other Therapeutic Areas

